[go: up one dir, main page]

WO2010137846A3 - 사포닌의 생체 이용률 증진 조성물 - Google Patents

사포닌의 생체 이용률 증진 조성물 Download PDF

Info

Publication number
WO2010137846A3
WO2010137846A3 PCT/KR2010/003288 KR2010003288W WO2010137846A3 WO 2010137846 A3 WO2010137846 A3 WO 2010137846A3 KR 2010003288 W KR2010003288 W KR 2010003288W WO 2010137846 A3 WO2010137846 A3 WO 2010137846A3
Authority
WO
WIPO (PCT)
Prior art keywords
saponin
bioavailability
increasing
composition
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/003288
Other languages
English (en)
French (fr)
Other versions
WO2010137846A2 (ko
Inventor
전희영
이지해
주경미
박찬웅
임경민
서대방
이상준
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to US13/322,102 priority Critical patent/US10172900B2/en
Priority to EP10780757.0A priority patent/EP2436388B1/en
Priority to JP2012512958A priority patent/JP6055309B2/ja
Priority to CN201080032779.5A priority patent/CN102458434B/zh
Priority to HK12105384.9A priority patent/HK1164702B/xx
Publication of WO2010137846A2 publication Critical patent/WO2010137846A2/ko
Publication of WO2010137846A3 publication Critical patent/WO2010137846A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)

Abstract

본 발명은 사포닌 생체 이용률 증진 인삼 복합 조성물을 개시한다. 또한, 사포닌의 생체 이용률을 증진시키는 오미자 추출물 및 맥문동 추출물 중 하나 이상을 포함하는 추출물을 개시한다.
PCT/KR2010/003288 2009-05-26 2010-05-25 사포닌의 생체 이용률 증진 조성물 Ceased WO2010137846A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/322,102 US10172900B2 (en) 2009-05-26 2010-05-25 Composition with improved bioavailabilty of saponin and method for improving the bioavailability of saponin
EP10780757.0A EP2436388B1 (en) 2009-05-26 2010-05-25 Composition for increasing the bioavailability of saponin
JP2012512958A JP6055309B2 (ja) 2009-05-26 2010-05-25 サポニンの生体利用率増進組成物
CN201080032779.5A CN102458434B (zh) 2009-05-26 2010-05-25 用于提高皂素的生物利用度的组合物
HK12105384.9A HK1164702B (en) 2009-05-26 2010-05-25 Composition with improved bioavailability of saponin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090045858A KR101593618B1 (ko) 2009-05-26 2009-05-26 사포닌의 생체 이용률 증진 조성물
KR10-2009-0045858 2009-05-26

Publications (2)

Publication Number Publication Date
WO2010137846A2 WO2010137846A2 (ko) 2010-12-02
WO2010137846A3 true WO2010137846A3 (ko) 2011-03-31

Family

ID=43223223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/003288 Ceased WO2010137846A2 (ko) 2009-05-26 2010-05-25 사포닌의 생체 이용률 증진 조성물

Country Status (6)

Country Link
US (1) US10172900B2 (ko)
EP (1) EP2436388B1 (ko)
JP (2) JP6055309B2 (ko)
KR (1) KR101593618B1 (ko)
CN (2) CN102458434B (ko)
WO (1) WO2010137846A2 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101593618B1 (ko) * 2009-05-26 2016-02-15 (주)아모레퍼시픽 사포닌의 생체 이용률 증진 조성물
KR101326005B1 (ko) * 2011-04-29 2013-11-07 재단법인 진안홍삼연구소 홍삼 농축액 및 과일 농축액을 함유하는 기능성 음료 조성물
CN114053320A (zh) * 2013-04-02 2022-02-18 株式会社爱茉莉太平洋 含有人参果提取物的组合物在制备改善女性性功能的药物中的用途
WO2015005554A1 (ko) * 2013-07-11 2015-01-15 (주)아모레퍼시픽 발모 및 육모 촉진용 조성물
CN104509926B (zh) * 2014-12-29 2016-08-24 通化百泉保健食品有限公司 人参、麦冬复合保健饮料及制备方法
CN104509909B (zh) * 2014-12-29 2016-09-07 通化百泉保健食品有限公司 人参、百合复合保健饮料及制备方法
CN104509912B (zh) * 2014-12-29 2016-12-07 通化百泉保健食品有限公司 人参、山胡萝卜复合保健饮料及制备方法
CN105031212B (zh) * 2015-07-07 2018-04-17 广东药学院 一种治疗帕金森病的药物
DE102015217418A1 (de) 2015-09-11 2017-03-16 Mühlbauer Technology Gmbh Radikalisch polymerisierbares Dentalmaterial
KR20170047008A (ko) * 2015-10-22 2017-05-04 (주)아모레퍼시픽 효소적 방법에 의하여 인삼의 사포닌으로부터 진세노사이드 Rd를 선택적으로 제조하는 방법
EP3308765B1 (de) 2016-10-17 2022-07-13 Mühlbauer Technology GmbH Radikalisch polymerisierbare verbindung
KR102505329B1 (ko) * 2022-10-17 2023-03-07 대동고려삼 주식회사 인지기능 개선 효과가 있는 소재를 이용한 홍삼 가공식품의 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138175A (ja) * 1993-11-17 1995-05-30 Pola Chem Ind Inc 人参サポニン製造法
JP2004049154A (ja) * 2002-07-23 2004-02-19 Hideo Hasegawa サポニン分解物を含む発酵人参およびその製造方法
JP2005531533A (ja) * 2002-04-08 2005-10-20 ホングリム トレーディング カンパニー リミテッド 加工処理された人参抽出物及びそれから分離されたサポニンの新規の使用
KR100555652B1 (ko) * 2002-04-08 2006-11-10 주식회사 진생사이언스 약효가 증강된 파낙스속 식물의 가공 추출물, 그 제조방법및 그를 함유하는 암 및 알러지 질환의 예방 및 치료를위한 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09110708A (ja) * 1995-08-11 1997-04-28 Taisho Pharmaceut Co Ltd 滋養強壮用生薬配合製剤
JPH11349487A (ja) * 1998-06-03 1999-12-21 Kwang Dong Pharmaceut Co Ltd 新しい処方の牛黄清心元組成物及びその製造方法
CN1116894C (zh) * 1999-03-09 2003-08-06 中国药科大学 治疗心血管病的药物
KR100364000B1 (ko) * 2000-04-26 2002-12-12 정풍한방제약주식회사 스포츠 음료 조성물 및 이의 제조 방법
JP2002275086A (ja) * 2001-03-15 2002-09-25 Fancl Corp 虚弱体質改善用組成物
KR100425022B1 (ko) * 2002-01-05 2004-03-27 롯데제과주식회사 가공인삼 추출물 및 이를 함유하는 약제 조성물
WO2003086438A1 (en) * 2002-04-08 2003-10-23 Ginseng Science Inc. Extract of processed panax genus plant, the preparation method thereof, and compositions containing the same
KR100572621B1 (ko) * 2003-03-19 2006-04-24 한국 한의학 연구원 비만 및 성인병 치료용 조성물
CN1234370C (zh) * 2003-09-30 2006-01-04 广州欧华医药生物技术有限公司 一种治疗心血管疾病和休克急救的中药注射剂
ES2384878T3 (es) * 2003-11-07 2012-07-13 Basf Beauty Care Solutions S.A.S. Uso cosmético de un extracto de la fruta de Schisandra chinensis
CN1296048C (zh) * 2003-12-19 2007-01-24 江苏正大天晴药业股份有限公司 参麦总皂甙滴丸及其制备方法
CN1317010C (zh) * 2005-03-08 2007-05-23 北京正大绿洲医药科技有限公司 一种用于强心益肾的滴丸及其制备方法
KR100692519B1 (ko) * 2005-03-17 2007-03-09 주식회사고려원인삼 냉온음료용 과립 홍삼 생맥산 및 이의 제조방법
US7884195B2 (en) * 2005-04-26 2011-02-08 Long Yun Li Method of extracting ginsengnoside Rg2m, pharmaceutical composition including ginsengnoside Rg2, and uses thereof
CN1868504A (zh) * 2005-05-24 2006-11-29 上海祥鹤制药厂 一种维肝福泰胶囊的制备方法
CN1939505A (zh) * 2005-09-26 2007-04-04 刘凤鸣 生脉饮滴丸及其制备方法
US7419689B2 (en) * 2005-11-15 2008-09-02 Access Business Group International Llc. Plant-based formulations for improving liver health
KR101234605B1 (ko) * 2005-11-24 2013-02-22 대동고려삼 주식회사 흑진삼 제조방법 및 그를 이용하여 제조된 흑진삼
CN101024034A (zh) * 2006-02-20 2007-08-29 陈文展 参芪消渴滴丸
CA2606971A1 (en) * 2006-10-18 2008-04-18 In-Hwan Seong Method for producing ginseng fruit and ginseng flower stalk with high content of ginsenoside
CN101028437B (zh) * 2007-04-03 2011-05-04 中国药科大学 一种防治心脑血管疾病的中药有效部位组合物及制备方法
KR100823940B1 (ko) * 2007-10-26 2008-04-22 (주)청구바이오 인삼 열매를 이용한 식품과 그 제조방법
KR101593618B1 (ko) * 2009-05-26 2016-02-15 (주)아모레퍼시픽 사포닌의 생체 이용률 증진 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138175A (ja) * 1993-11-17 1995-05-30 Pola Chem Ind Inc 人参サポニン製造法
JP2005531533A (ja) * 2002-04-08 2005-10-20 ホングリム トレーディング カンパニー リミテッド 加工処理された人参抽出物及びそれから分離されたサポニンの新規の使用
KR100555652B1 (ko) * 2002-04-08 2006-11-10 주식회사 진생사이언스 약효가 증강된 파낙스속 식물의 가공 추출물, 그 제조방법및 그를 함유하는 암 및 알러지 질환의 예방 및 치료를위한 조성물
JP2004049154A (ja) * 2002-07-23 2004-02-19 Hideo Hasegawa サポニン分解物を含む発酵人参およびその製造方法

Also Published As

Publication number Publication date
CN104688791B (zh) 2018-04-27
JP6053873B2 (ja) 2016-12-27
EP2436388A4 (en) 2012-11-28
EP2436388A2 (en) 2012-04-04
CN102458434B (zh) 2015-03-25
KR20100127420A (ko) 2010-12-06
JP2012528144A (ja) 2012-11-12
CN102458434A (zh) 2012-05-16
WO2010137846A2 (ko) 2010-12-02
US10172900B2 (en) 2019-01-08
US20120076874A1 (en) 2012-03-29
EP2436388B1 (en) 2016-03-23
KR101593618B1 (ko) 2016-02-15
JP2015164955A (ja) 2015-09-17
HK1164702A1 (en) 2012-09-28
CN104688791A (zh) 2015-06-10
JP6055309B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
WO2010137846A3 (ko) 사포닌의 생체 이용률 증진 조성물
PL2570132T3 (pl) Sposób wytwarzania nowego obrobionego żeńszenia, albo jego ekstraktu, w którym zwiększono zwykle niską zawartość ginsenozydu
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010146463A3 (en) Composition comprising rebaudioside d for reducing or eliminating aftertaste and preparation method thereof
WO2011055231A3 (en) Rebaudioside a polymorphs and methods to prepare them
WO2010118866A8 (en) Trehalulose-containing composition, its preparation and use
WO2011019986A3 (en) Processes for preparing pemetrexed
WO2010049454A3 (en) Antimicrobial composition from copepods
WO2008149345A3 (en) Tri-aryl compounds and compositions comprising the same
MY172673A (en) Non-alcohol, beer-taste beverage having substantiality in taste
GB0807673D0 (en) Polyphenolic extract
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2011058525A3 (en) Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2010065586A3 (en) Preparation of capecitabine
EP2225952A4 (en) PROCESS FOR PRODUCING PURIFIED TEA EXTRACT
WO2013076743A3 (en) Process for the purification of polyaminocarboxylates
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010079013A3 (en) Umami active fraction, method to prepare the same, method of enhancing umami taste and method of preparing a food product
WO2011023954A3 (en) Polymorphic forms of manidipine
MX339772B (es) Metodo y composicion para producir azucar clarificada.
WO2011018771A3 (en) Process for the preparation of valganciclovir hydrochloride
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
WO2009010377A3 (en) Process for preparing platelet-like (embossed) particles
WO2011058423A3 (en) Identification and characterization of natural chemical entities by liquid chromatography and mass spectrometry lc-ms/ms and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080032779.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10780757

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13322102

Country of ref document: US

Ref document number: 2010780757

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012512958

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE